The cutbacks are significant. Lilly will slice its planned investment of 2.3 billion euros ($2.7 billion) in half, while ...
Nearly a decade later, taking the center stage at ASCO 2026, Akeso’s ivonescimab made history by offering the first-ever ...
The FDA has hit QOL Medical with an untitled letter over emails about Sucraid, accusing the company of creating a misleading impression about the indication for the rare disease drug. FDA officials ...
Pharma solutions firm Cencora and Gilead Sciences have expanded their longstanding partnership, cutting a deal in which the distribution giant will support access to Gilead's CAR-T cancer therapies ...
Amid shifts in attitudes around family planning and contraception—and as the advent of telehealth outfits like Hims & Hers ...
More biopharma layoffs are hitting New Jersey, this time from Merck & Co.in the latest phase of headcount reductions ...
After submitting its timed-release version of a decades-old ADHD drug to the FDA nearly a year ago, Kansas City's Cingulate ...
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...
ViiV Healthcare is teaming up with TV personality, HIV and LGBTQ advocate Michelle Visage to help broaden awareness about new ...
The nonprofit, The Endometriosis Collective, has included Schumer and Monroe in the feature-length documentary “End of the ...
AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new ...
A phase 3 study of Gilead’s Livdelzi has met its primary endpoint, showing the drug's ability to normalize a key marker of disease progression for those with the rare liver disorder primary biliary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results